Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.34 |
| ▸ | CTSD | P07339 | 2/20 | 0.34 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.30 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7948333 | 0.88 | BACE1 (0.42) | BACE1CTSD | |
| SCHEMBL2377903 | 0.81 | AKR1B1 (0.37) | BACE1CTSDDYRK3PIM1DYRK1A | |
| SCHEMBL12245589 | 0.81 | AKR1B1 (0.37) | BACE1CTSDDYRK3PIM1DYRK1A | |
| SCHEMBL2376310 | 0.81 | AKR1B1 (0.37) | BACE1CTSDDYRK3PIM1DYRK1A | |
| SCHEMBL7956475 | 0.79 | BACE1 (0.54) | BACE1CTSD | |
| SCHEMBL2376958 | 0.68 | SCN9A (0.37) | BACE1CTSDPIM1 | |
| SCHEMBL1828658 | 0.68 | AKR1B1 (0.38) | BACE1CTSD | |
| SCHEMBL2375565 | 0.68 | BACE1 (0.46) | BACE1CTSD | |
| SCHEMBL2375775 | 0.68 | BACE1 (0.46) | BACE1CTSD | |
| SCHEMBL12246268 | 0.65 | BACE1 (0.41) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| WO-2010021680-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | BACE1, BACE2, APP | BACE1 1/4885CTSD 43/4885DYRK3 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.